Boston Scientific Corporation
BSXUSBoston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Enterprise value over trailing (LTM) vs. forward (NTM) fundamentals. Click an LTM cell to chart it.
- Sector
- Medical Devices & Diagnostics
- Sub-sector
- Surgical & Interventional Devices
- Listing
- BSX
- Country
- US
EV / LTM Revenue
Annual financials & analyst forecasts
| $M | CY2021 | CY2022 | CY2023 | CY2024 | CY2025 | CY2026E | CY2027E |
|---|---|---|---|---|---|---|---|
| Revenue YoY | — | 7% | 12% | 18% | 20% | 6% | 4% |
| Revenue | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B | $21.34B | $22.27B |
| Gross Profit | $7.38B | $7.71B | $8.83B | $10.29B | $13.85B | — | — |
| Gross Profit Margin | 62.1% | 60.8% | 62.0% | 61.4% | 69.0% | — | — |
| EBITDA | $2.52B | $2.77B | $3.45B | $3.92B | $5.27B | $4.95B | $5.17B |
| EBITDA Margin | 21.2% | 21.8% | 24.2% | 23.4% | 26.3% | 23.2% | 23.2% |
| EBIT | $1.77B | $1.84B | $2.18B | $2.65B | $3.97B | $3.20B | $3.34B |
| Net Income | $1.04B | $699M | $1.59B | $1.85B | $2.89B | $4.88B | $5.04B |
| Free Cash Flow | $1.32B | $918M | $1.70B | $2.44B | $3.63B | — | — |
| FCF Margin | 11.1% | 7.2% | 12.0% | 14.6% | 18.1% | — | — |
| Short-Term Debt | $261M | $20M | $531M | $1.78B | $389M | — | — |
| Long-Term Debt | $8.80B | $8.91B | $8.57B | $8.84B | $11.46B | — | — |
| Cash & Cash Equivalents | $1.93B | $928M | $865M | $414M | $2.04B | — | — |
| Net Debt | $7.13B | $8.00B | $8.23B | $10.21B | $9.80B | — | — |
| Net Debt / EBITDA | 2.8x | 2.9x | 2.4x | 2.6x | 1.9x | — | — |
| Rule of 40 | — | 13.9% | 24.2% | 32.2% | 37.9% | — | — |